Advertisement · 728 × 90
#
Hashtag
#Trop2
Advertisement · 728 × 90
Post image

Antibody Therapeutics (IF=4.5, Oxford University Press)
🔹 Affinity-optimized TROP2 antibodies support potent antitumor activity in antibody–drug conjugates
academic.oup.com/abt/advance-...
#ADC #TROP2 #CancerResearch #TargetedTherapy

0 0 0 0
Preview
第一三共、Dato-DXdのTNBC一次治療でFDA優先審査──TROPION-Breast02に基づく生物学的製剤一部変更承認申請が受理 | STELLANEWS.LIFE STELLANEWS.LIFE(ステラニュース・ライフ)は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE(ステラニュース・ライフ)は、科学や技術、医薬品分野における最新の研究成果や発見

第一三共、Dato-DXdのTNBC一次治療でFDA優先審査──TROPION-Breast02に基づく生物学的製剤一部変更承認申請が受理
FDA grants Priority Review for datopotamab deruxtecan in first-line TNBC based on TROPION-Breast02

stellanews.life/technology/8...

#TNBC #BreastCancer #DatoDXd #TROP2 #FDA #PriorityReview

0 0 0 0
Preview
OBI Pharma Presents Preclinical Results for Bispecific ADC OBI-201 at SABCS 2025 - OBI Pharma 台灣浩鼎 Highlighting OBI-201’s Antitumor Activity and Payload Delivery Performance Across Multiple Tumor Animal Models OBI Pharma (4174.TWO) presented the preclinical results of OBI-201, at the 2025 San Anton...

🎉OBI presented new preclinical results for our bispecific ADC OBI-201 at
@sabcs.bsky.social #SABCS2025, led by our CSO Ya-Chi Chen and the R&D team.
#OBIPharma #OBI201 #ADC #BispecificADC #SABCS2025 #BreastCancerResearch #TROP2

www.obipharma.com/news/obi-201...

1 0 0 0

🎉 OBI-902 receives a Second FDA Orphan Drug Designation, this time for gastric cancer including gastroesophageal junction adenocarcinoma.
We remain committed to advancing OBI-902 in areas of high unmet medical need. 🔬
#ADC #OBI902 #TROP2 #GlycOBI #ODD #GC #GEJC

www.obipharma.com/news/obi-902...

0 0 0 0
Video

China NMPA Approves Secituzumab Tirumotecan for Injection

📩 info@dengyuemed.com
🔗https://dengyuemed.com

#ChinaNMPA #DrugApproval #SecituzumabTirumotecan #ADC #TROP2 #TripleNegativeBreastCancer #KelunBiotech #Jiatailai

0 0 0 0
Post image

#KelunBiotech has picked up another first for its #TROP2 targeting antibody-drug conjugate (#ADC) sacituzumab tirumotecan (sac-TMT), after getting Chinese approval of the drug in #nonsmallcelllungcancer (NSCLC).

pharmaphorum.com/news/kelun-g...

0 0 0 0
Post image

Dr. David Rimm + @yalepathology.bsky.social colleagues have developed Troplex, a test that measures #HER2 & #TROP2 levels in #breastcancer tumors—helping oncologists choose the most effective antibody-drug conjugates. bit.ly/457oUp7
@ascocancer.bsky.social

1 1 0 0
Preview
Akeso Launches First Bispecific ADC, Strengthening Its Leadership in Cancer Therapies Akeso, Inc. has announced the enrollment of the first patient in Phase Ia clinical trials for its bispecific ADC targeting Trop2 and Nectin4, marking a significant advancement.

Akeso Launches First Bispecific ADC, Strengthening Its Leadership in Cancer Therapies #Hong_Kong #Akeso #TROP2 #Nectin4

0 0 0 0
Preview
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC - OBI Pharma 台灣浩鼎 OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology. TAIPEI, Taiwan, May 1, 2025 — OBI Pharma, Inc. (“OBI”), a clinical stage oncology company (4174.TWO), today...

🔔U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technology.
#ADC #GlycOBI #Trop2 #OBIPharma #INDClearance

Learn more:
www.obipharma.com/news/obi-pha...

1 0 0 0
Preview
TROPHIT1—a randomized, open-label, multicenter, phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic colorectal cancer patients Colorectal cancer (CRC) ranks among the most common malignancies worldwide. Response rates to standard-of-care (SOC) treatment drop sharply beyond the…

🚨 We’re excited to announce a clinical trial targeting #TROP2 in advanced #colorectal #cancer. Learn more about it: @dkfz.bsky.social
www.sciencedirect.com/science/arti...

5 3 1 0
Preview
KisoJi Biotechnology Secures $41 Million to Propel Antibody Development and AI Innovations KisoJi Biotechnology raises $41 million to advance its leading antibody program KJ-103 and enhance AI capabilities in development for key diseases.

KisoJi Biotechnology Secures $41 Million to Propel Antibody Development and AI Innovations #Canada #Montreal #KisoJi_Biotech #TROP2 #KJ-103

0 0 0 0

Galadriel's "Heal yourself" to Sauron was just the perfect "F-you" response that I'm still giggling in sheer delight at it.
#TRoP #Tolkien #TRoP2

2 0 0 0